Presence of a functional receptor for GLP‐1 in osteoblastic cells, independent of the cAMP‐linked GLP‐1 receptor
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Glucagon‐like peptide 1 (GLP‐1) controls glucose metabolism in extrapancreatic tissues through receptors other than the pancreatic cAMP‐linked GLP‐1 receptor; also, GLP‐1 induces an insulin‐ and PTH‐independent bone anabolic action in insulin‐resistant and type‐2 diabetic rats. Here we searched for the presence and characteristics of GLP‐1 receptors in osteoblastic MC3T3‐E1 cells. [125 I]‐GLP‐1 specific binding to MC3T3‐E1 cells was time‐ and temperature‐dependent, reaching maximal value at 30 min at 25°C; in these conditions, [125 I]‐GLP‐1 binding was dissociable, and displaced by GLP‐1, partially by GLP‐2, but not by exendin‐4 (Ex‐4), exendin‐9 (Ex‐9), glucagon or insulin; Scatchard analysis of the unlabeled GLP‐1 data showed high and low affinity binding sites; cross‐linking of GLP‐1 binding revealed an estimated 70 kDa band, almost undetectable in the presence of 10−6 M GLP‐1. GLP‐1, Ex‐9, insulin or glucagon failed to modify cellular cAMP content, while GLP‐2 and Ex‐4 increased it. However, GLP‐1 induced an immediate hydrolysis of glycosylphosphatidylinositols (GPIs) generating short‐lived inositolphosphoglycans (IPGs), and an increase in phosphatidylinositol‐3 kinase (PI3K) and mitogen activated protein kinase (MAPK) activities; Ex‐4 also affected GPIs, but its action was delayed with respect to that of GLP‐1. This incretin was found to decrease Runx2 but increased osteocalcin gene expression, without affecting that of osteoprotegerin or the canonical Wnt pathway activity in MC3T3‐E1 cells which do not express the pancreatic GLP‐1 receptor. Our data demonstrate for the first time that GLP‐1 can directly and functionally interact with osteoblastic cells, possibly through a GPI/IPG‐coupled receptor. J. Cell. Physiol. 225: 585–592, 2010. © 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass
Xie, D., Zhong, Q., Ding, K.-H., Cheng, H., Williams, S., Correa, D., Bollag, W. B., Bollag, R. J., Insogna, K., Troiano, N., et al. (2007) · Bone · doi:10.1016/j.bone.2007.01.007 · Cited by 144
Sancho, V., Trigo, M. V., González, N., Valverde, I., Malaisse, W. J., & Villanueva-Peñacarrillo, M. L. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01747 · Cited by 78 · cited 2×
“…and lipid metabolism in extrapancreatic tissues such as liver, skeletal muscle and fat (Valverde et al., 1994; Villanueva-Peñacarrillo et al., 1994; Sancho et al., 2005), which are exerted through specific receptors (Valverde et al., 1993; Delgado et al., 1995; Villanueva-Peñacarrillo et al.,…”
BackgroundSelf-citation
Cited by
Mechanisms of diabetes mellitus-induced bone fragility
On behalf of the IOF Bone and Diabetes Working Group, Napoli, N., Chandran, M., Pierroz, D. D., Abrahamsen, B., Schwartz, A. V., & Ferrari, S. L. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.153 · Cited by 1,107
BMI and BMD: the potential interplay between obesity and bone fragility
Palermo, A., Tuccinardi, D., Defeudis, G., Watanabe, M., D’Onofrio, L., Lauria Pantano, A., Napoli, N., Pozzilli, P., & Manfrini, S. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13060544 · Cited by 197
Iepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1176 · Cited by 193
“So far, studies have failed to demonstrate the presence of GLP-1 receptors on osteoblasts (28, 29), but it has been suggested that GLP-1 may interact with osteoblastic cells through a glycosylphosphatidylinositol (GPI)/ inositolphosphoglycan (IPG)-coupled receptor (30).”
BackgroundDing, L., Sousa, K. M., Jin, L., Dong, B., Kim, B., Ramirez, R., Xiao, Z., Gu, Y., Yang, Q., Wang, J., et al. (2016) · Hepatology · doi:10.1002/hep.28689 · Cited by 184
Kim, J.-Y., Lee, S.-K., Jo, K.-J., Song, D.-Y., Lim, D.-M., Park, K.-Y., Bonewald, L. F., & Kim, B.-J. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.01.001 · Cited by 137
Pereira, M., Jeyabalan, J., Jørgensen, C. S., Hopkinson, M., Al-Jazzar, A., Roux, J. P., Chavassieux, P., Orriss, I. R., Cleasby, M. E., & Chenu, C. (2015) · Bone · doi:10.1016/j.bone.2015.08.006 · Cited by 137
Lu, N., Sun, H., Yu, J., Wang, X., Liu, D., Zhao, L., Sun, L., Zhao, H., Tao, B., & Liu, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132744 · Cited by 108
“Both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors have been shown to be expressed on osteoblasts [11, 33, 34].”
BackgroundGLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia
Nuche-Berenguer, B., Lozano, D., Gutiérrez-Rojas, I., Moreno, P., Mariñoso, M. L., Esbrit, P., & Villanueva-Peñacarrillo, M. L. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0015 · Cited by 96
Self-citationWu, X., Li, S., Xue, P., & Li, Y. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.018 · Cited by 92
“However, the inability of Nuche-Berenguer and colleagues to detect pancreatic GLP-1R in the same cell line may be due in part to differences in the size of the amplification template [45].”
BackgroundResultInfluentialDriessen, J. H. M., Henry, R. M. A., van Onzenoort, H. A. W., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., Neef, C., Leufkens, H. G. M., & de Vries, F. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-9993-5 · Cited by 79
“The pathways through which GLP1-ra’s may act on bone metabolism are not fully elucidated, but it has been suggested that GLP1-ra’s may, either directly or indirectly, shift the balance in bone homeostasis towards bone formation [26], via receptor coupling on osteoblasts [27] and (or) thyroid C cells [28, 29].”
The effects of GLP-1 agonists on musculoskeletal health and orthopedic care
Gatto, A., Liu, K., Milan, N., & Wong, S. (2025) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-025-09978-3 · Cited by 55
Metadata
- Authors
- Nuche‐Berenguer, B., Portal‐Núñez, S., Moreno, P., González, N., Acitores, A., López‐Herradón, A., Esbrit, P., Valverde, I., & Villanueva‐Peñacarrillo, M. L.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2010-05-19
- Volume
- 225
- Issue
- 2
- Pages
- 585-592
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2064367148
- Cited by
- 146
- References
- 5
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.